PureTech Health Plc (id:3506 PRTC)
156.40 GBP
Opening hours: 08:00 - 16:30 (GMT Standard Time: 12/24/2024 1:08:32 AM)
Exchange closed, opens in 6 hours 51 minutes
About PureTech Health Plc
Market Capitalization 405.09M
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Headquarters (address) |
6 Tide Street Boston 02210 MA United States |
| Phone | 617 482 2333 |
| Website | https://www.puretechhealth.com |
| Employees | 90 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PRTC |
| Exchange | London Stock Exchange |
| Currency | GBP |
| 52 week range | 138.75 - 238.50 |
| Market Capitalization | 405.09M |
| P/E trailing | -644.17 |
| P/E forward | -3.88 |
| Price/Sale | 865.59 |
| Price/Book | 126.46 |
| Beta | 3.00 |
| EPS | 3.00 |
| EPS United States (ID:6, base:3382) | 24.33 |